ABSTRACT:
Purpose: One of the principal biochemical characteristics of malignant cells compared to normal cells is a metabolic switch from oxidative phosphorylation to increased glycolysis, even under hypoxic conditions, and is termed the Warburg effect [1]. Lactate dehydrogenase (LDH) catalyzes the conversion of pyruvate to lactate and is considered to be a key checkpoint of anaerobic glycolysis. It is elevated in many types of cancers and has been linked to tumor growth, maintenance, and invasion; therefore, its inhibition may restrict the energy supply in tumors and thereby reduce the metastatic and invasive potential of cancer cells. This enzyme is receiving a great deal of attention as a potential diagnostic marker or a predictive biomarker for many types of cancer and as a therapeutic target for new anticancer treatment. [2] Lactate dehydrogenase (LDH) is an enzyme involved in anaerobic glycolysis and regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR)–containing complex 1 (PI3K/Akt/TORC1) pathway as well as tumor hypoxia/necrosis This study aimed to investigate whether baseline lactic dehydrogenase (LDH) level, which is a marker of hypoxia, had clinical value in determining therapeutic response and prognosis for cancer patients. High serum LDH levels are associated with poor prognosis in patients with cancer [3] Patients and Methods: We evaluated pretreatment and post-treatment serum LDH in 100 cancer patients, with a median follow- up of 12 months statistical analysis: The Shapiro- Wilk test was used to determine the distribution of continuous variables. Student’s t-test, chi square, and Ficher exact test were used too. [4] Results: Baseline LDH levels 210 IU/L was an independent prognosticator for recurrence-free survival. The predictive value of baseline LDH value remained significant in the subgroup analysis. LDH level <227 IU/L was identified as an independent predictor of complete remission after treatment. It helps distinguish patients with different prognosis and select patients who are more likely to benefit from normal treatment regimens. A highly significant difference was found between the survival patterns of patients with LDH levels of 233 U or less and those with LDH levels greater than 233 U. (recurrence free survival rates were 63% and 74%, respectively. Discussion: The association of LDH level with survival was evident even after adjustment for other factors of potential prognostic significance. Pretreatment serum LDH determinations may provide a useful means of stratifying patient populations when comparing treatment programs for cancer types.
Cite this article:
Randa Nasser, Firas Hussein. Corelation between Pretreatment Serum LDH levels and Therapeutic response in Cancer patients. Research J. Pharm. and Tech 2020; 13(3): 1107-1112. doi: 10.5958/0974-360X.2020.00203.6
Cite(Electronic):
Randa Nasser, Firas Hussein. Corelation between Pretreatment Serum LDH levels and Therapeutic response in Cancer patients. Research J. Pharm. and Tech 2020; 13(3): 1107-1112. doi: 10.5958/0974-360X.2020.00203.6 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-3-8
REFERENCES:
1.
Yang, W., Zheng,
Y., Xia, Y., Ji, H., Chen, X., et al. (2012) ERK1/2-dependent phosphorylation
and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell. Biol.
14, 1295–1304
2.
Fantin, V. R.,
St-Pierre, J., and Leder, P. (2006) Attenuation of LDH-A expression uncovers a
link between glycolysis, mitochondrial physiology, and tumor maintenance.
Cancer Cell 9, 425–434
3.
DiLuna ML, King JT Jr, Knisely JP, Chiang VL. Prognostic factors for
survival after stereotactic radiosurgery vary with the number of cerebral
metastases. Cancer. 2007;109:135-145
4.
Armitage P.
Statistical Methods in Medical Research. New York: John Wiley and Sons,
1971:363-365.
5.
Bagley CM Jr,
DeVita VT Jr, Berard CW, Canellos GP. Advanced lymphosarcoma: intensive
cyclical combination chemotherapy with cyclophosphamide, vincristine and
prednisone. Ann Intern Med 1972; 76~227-234.
6.
Semenza, G. L.
(2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60,
591–597.
7. Diaz, Leslie K MD, Sneige,
Nour MD. Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys
to Increasing Testing Accuracy. Advances in Anatomic Pathology 2005;
12(1):10-19
8.
Zhao, Y., Liu,
H., Riker, A. I., Fodstad, O., Ledoux, S. P., et al. (2011) Emerging metabolic
targets in cancer therapy. Front. Biosci. 16, 1844–1860
9.
Arseneau JC,
Canellos GP, Banks PM, Berard CW, Gralnick HR, DeVita VT Jr. American Burkitt’s
lymphoma: A clinicopathologic study of 30 cases. 1. Clinical factors relating
to prolonged survival. Am J Med 1975; 58:314-321.
10. Damle, N. K.; Frost, P. Curr.
Opin. Pharmacol. 2003, 3, 386-90
11. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E.,
Gatter, K. C., and Harris, A. L. (2006) Lactate dehydrogenase 5 expression in
operable colorectal cancer: strong association with survival and activated
vascular endothelial growth factor pathway—a report of the Tumour Angiogenesis
Research Group. J. Clin. Oncol. 24, 4301–4308
12. Dang, C. V. (1999) c-Myc
target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell.
Biol. 19, 1–11.
13. Anderson T, Magrath I, Brereton H, Ziegler J, Schein
P. Burkitt’s lymphomas: prediction of early relapse and metabolic complications
of therapy. Proc Am Assoc Cancer Res 1974; 15:169.
14. Leung SF, Chan KC, Ma BB, et
al. Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course
predicts
15. Dang, C. V. (2004) The interplay between MYC and HIF
in the Warburg effect. Ernst Schering Found. Symp. Proc 4, 35 – 53
16. Dang, C. V. (1999) c-Myc target genes involved in cell
growth, apoptosis, and metabolism. Mol. Cell. Biol. 19, 1–11.
17. Dang, C. V., Le, A., and Gao,
P. (2009) MYC-induced cancer cell energy metabolism and therapeutic
opportunities. Clin. Cancer Res. 15, 6479–6483.